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The constitutive degradation of membrane components takes place in the acidic compartments of a
cell, the endosomes and lysosomes. Sites of lipid degradation are intralysosomal membranes that
are formed in endosomes, where the lipid composition is adjusted for degradation. Cholesterol is
sorted out of the inner membranes, their content in bis(monoacylglycero)phosphate increases,
and, most likely, sphingomyelin is degraded to ceramide. Together with endosomal and lysosomal
lipid-binding proteins, the Niemann–Pick disease, type C2-protein, the GM2-activator, and the sapo-
sins sap-A, -B, -C, and -D, a suitable membrane lipid composition is required for degradation of com-
plex lipids by hydrolytic enzymes.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. The stomach of the cell
Within the acidic compartments, the endosomes and lyso-
somes, macromolecules, complex lipids, and oligosaccharides are
degraded into their building blocks by hydrolytic enzymes [1].
The resulting catabolites are exported from the lysosome and re-
used in cellular metabolism. This export is mediated by transport
proteins present in the limiting lysosomal membrane [2,3]. In gen-
eral, these transporters make use of the energy conserved in the
proton gradient along the perimeter membrane and co-transport
small molecules or ions together with protons. Many transporters,
among them those for amino acids, cystine, dipeptides, inorganic
ions, sialic acids, and inositol, have been characterized. Only re-
cently, transport proteins for hexoses (GLUT-8) [4,5] and for cobal-
amin [6] were identiﬁed. Cobalamin, essential for degradation ofchemical Societies. Published by E
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olism, is delivered to the cell via the lysosomes, which illustrates
the role of lysosomes for cellular nutrition.
Soon after their recognition, lysosomes have been regarded as a
kind of intracellular stomach that provides the cell with nutrients.
Not only cobalamin-bound cobalt-ions, also other metal ions like
iron ions [7], which are essential for many cellular processes from
oxygen-transport to respiration are delivered or recycled through
the endo/lysosomal compartment. While several of the transport
proteins for the degradation products of water-soluble macromol-
ecules have been identiﬁed, together with their role in human dis-
eases such as cystinosis and Salla-disease (sialic acid transporter
deﬁciency), putative transport proteins for the ﬁnal degradation
products of membrane lipids, fatty acids and sphingosine, are not
known. These substances serve not only as building blocks in
membrane recycling, but can also be further degraded in the cyto-
plasm, or can be receptor ligands or precursors thereof and partic-
ipate in the regulation of cell function. In dependence of their
degree of saturation, fatty acids are ligands of nuclear receptors
[8] and sphingosine-1-phosphate [9] derived from sphingosine
acts as a ﬁrst and second messenger.
About 25 proteins that reside within the limiting lysosomal
membrane have been characterized in structural and functional
terms, including pathobiochemical aspects [10,11], but their func-
tion is not known in every case. In addition, about 60 proteins,
which are present in the lumen of the lysosome, are known, many
of them for a long time, also because of their role in monogeniclsevier B.V. All rights reserved.
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Recently, new lysosomal proteins have been discovered in proteomic
studies [12]. Among them are the N-acylsphingosine amidohydro-
lase, an acid ceramidase-like protein that acts as a N-acylethanol-
amine-hydrolyzing acid amidase, ribonucleases 1, 6 and T2, and
proteins of currently unknown function such as acid sphingomye-
linase-like phosphodiesterase 3a, arylsulfatases G and K, or man-
nose-6-phosphate protein P76.
2. pH-value
A characteristic feature of the acidic compartments is the low
pH of endosomes (pH 5–6) and lysosomes (pH 4.6–5) [13]. This
pH is generated by the action of V-type ATPases and serves various
functions [14]. For example, after receptor-mediated endocytosis,
internalized cargo such as LDL, but not transferrin, is released from
its receptor, which, in turn, is recycled to the plasma membrane or
– together with other proteins of the plasma membrane – sorted to
intraluminal vesicles by a complex molecular machinery and then
degraded in the lysosomes [15]. Soluble proteins that are targeted
in the TGN to lysosomes dissociate at the acidic pH from their
receptor, usually a mannose-6-phosphate receptor, but also, in
the case of glucosylceramide-beta-glucosidase, the membrane pro-
tein LIMP-2 [16]. Also, the maturation from endosomes to lyso-
somes, and the formation of intraluminal membranes at the
stage of late endosomes, the multivesicular body, requires acidic
pH (and calcium ions) [17]. The lysosomal pH is also required
not only for optimal activity of hydrolytic enzymes in the lumen,
but can contribute to their stability in the presence of proteolytic
enzymes: due to their isoelectric points, some soluble lysosomal
enzymes such as acid sphingomyelinase are positively charged in
the acidic environment of the lysosome. As polycations, they ad-
here to the surface of intralysosomal membranes that bear a neg-
ative charge due to the presence of the acidic lysosomal lipid
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Fig. 1. Structures of selected glycosphingolipids (gangliosides GM1, GM2, GM3, glucosy
Please note that the acyl residues are on the sn2-positions of both glycerol backbones acc
occur from the sn2- to the sn3-position.are protected from attack by acid hydrolases. Their release from
these membranes by cationic amphiphilic drugs like desipramine
(Fig. 1) leads to their premature degradation [18,19] in the case
of acid sphingomyelinase with the consequence of a drug-induced
lipidosis. Compared to lysosomes, the higher pH of early, but not of
late endosomes can be attributed to the action of Na,K-ATPase,
which, like V-ATPase, is electrogenic, contributes to the positive
potential of the lumen and thereby limits proton inﬂux [20]. Other
factors such as regulation of V-ATPase by its membrane environ-
ment, chloride channels, and luminal buffer systems might addi-
tionally account for the lower acidiﬁcation of endosomes [21]
and the vacuole of yeast [22]. In cell culture, endosomal pH can
vary between different cell types, and also values below pH 4 are
theoretically possible [23].
3. Ions from the outside: iron
Together with the peptide portion of many proteins, metal ions
such as iron [24], copper [25], and zinc are recycled during autophagy
in the lysosomes or taken up from the outside. Zinc and copper
ions can be bound to lysosomal metallothionein from which they
are released during acidiﬁcation. Non-dividing cells can meet their
requirement for iron ions largely by degradation of iron-containing
proteins after autophagy. For this reason, and also for the removal
of aberrant proteins, autophagy is a vital process and required for
the survival especially for neuronal cells, as indicated by the obser-
vation that loss of Atg7, a gene required for autophagy, leads to ra-
pid neurodegeneration in mice [26].
Exogenous supply of iron ions and their delivery through the
endolysosomal system is essential for dividing cells. After uptake
of transferrin, the decrease of the endosomal pH leads to the re-
lease of iron ions from receptor-bound transferrin. These ions leave
the endolysosomal compartment via the divalent metal-trans-
porter-1 to the cytoplasm or via membrane contacts with the outer
mitochondrial membrane. Regulation of the amount of ferritin andOH
O
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ording to the proposed biosynthesis of BMP [67], but that acyl migration is known to
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minimal levels of free iron ions to prevent the formation of hydro-
xyl radicals via the Fenton reaction:
Fe2þ þH2O2 ! Fe3þ þ OH þ OH ð1Þ
While the primary reduction product of dioxygen, the hyperox-
ide (superoxide) radical O2 , is not particularly reactive, the OH-
radical is one of the most reactive free radical species known.
Hydrogen peroxide required for the Fenton reaction is produced
by respiratory chain enzymes or oxidoreductases and is present
at low concentrations. The presence of reducing agents in the lyso-
sol favors Fe(II) formation at acidic pH. Hemosiderin, apparently an
intralysosomal aggregation- and degradation product of ferritin,
and eventually also of other iron-rich non-degradable proteins
within lipofuscin accumulate, so that certain lysosomal popula-
tions can develop sensitivity towards oxidative stress. This can lead
to oxidation and misfolding of proteins, to peroxidation of lipids
present in the limiting membrane with subsequent leakage, to im-
paired autophagy, and might constitute a factor for ageing [27].
Oxidative stress mediated by iron ions might account for the obser-
vation that tissues from Niemann–Pick disease, type C1-protein
(NPC1) knockout mice show increased levels of potentially athero-
genic cholesterol autoxidation products [28] with hydroxy groups
in positions 5, 6, or 7, while the levels of enzymatically formed 27-
hydroxycholesterol are decreased [29].
4. Lysosomal diseases
Defects in enzymes and proteins required for lysosomal catabo-
lism lead to inherited diseases, the lysosomal storage diseases.
They can be classiﬁed according to the stored substances, as sphin-
golipidoses, mucopolysaccharidoses, mucolipidoses, glycoprotein-
and glycogen storage diseases [30,31]. Impairment of membrane
degradation is especially visible in defects of sphingolipid and gly-
cosphingolipid catabolism. In contrast to other lipid classes, a
whole group of diseases is known, which is caused by defects in
this pathway. A reason for this is that glycosphingolipids are de-
graded in a sequential manner. Understanding of pathogenesis
[32], and improvements in diagnosis and therapy of sphingolipi-
doses [33] is an ongoing challenge. Investigation of human patients
[34], genetically engineered mammals [35], and other organisms
[36] allowed insight into various aspects of lysosomal catabolism,
including membrane metabolism and transport. A characteristic
feature of several sphingolipidoses is that the primary defect leads
to incomplete degradation of complex lipids. Due to their insolubil-
ity, they co-precipitate other hydrophobic substances, lipids and
proteins, as secondary storage products [37]. This kind of trafﬁc
jam [38,39] occurs, e.g., in Niemann–Pick disease, type C, in the
sense that NPC1 dysfunction leads to the accumulation not only
of cholesterol, but also of sphingomyelin, glycosphingolipids,
sphingosine, and others in multilamellar storage bodies [40].
Sphingosine causes also calcium depletion and a subsequent defect
of endocytosis, as demonstrated for NPC1-disease, in which sphin-
gosine accumulation appears to be one of the ﬁrst measurable ef-
fects after induction of the disease [41].
Trafﬁc jam can impair lysosomal function, such as nutrient
delivery through the endolysosomal system. For example, iron
homeostasis is impaired in animals of two glycolipid storage dis-
eases, the GM1- and the 0-variant of the GM2 gangliosidoses,
Sandhoff-disease. Supplementation of the animals with iron ions
improved their condition and increased their life expectancy by
nearly 40% [42]. This illustrates the role of the endolysosomal sys-
tem as a stomach and adds another factor that contributes to the
pathogenesis of these diseases. Another observation of relevance
for both the understanding of lysosomal storage diseases and thefunction of lysosomes is that autophagy can be blocked as a gen-
eral feature of lysosomal storage or, alternatively, can be increased,
e.g., investigation of mouse models of Multiple Sulfatase Deﬁciency
and Mucopolysaccharidosis, type IIIA, showed accumulation of
polyubiquitinated proteins and of dysfunctional mitochondria.
Neurodegeneration in storage diseases and in unrelated late-onset
neurodegenerative disorders might share altered autophagy as
common mechanism [43,44].
Most lysosomal storage diseases are caused by the primary de-
fect of a lysosomal protein. However, defects in proteins of non-
lysosomal localization can also lead to a lysosomal disease, which
is the case in multiple sulfatase deﬁciency, mucolipidosis II/III, and
Niemann–Pick disease, type C1, a defect in endosomal cholesterol
efﬂux [45]. In addition, several developmental disorders with neu-
rodegenerative phenotypes can be caused by defects in function-
ally unrelated enzymes, which affect lysosomal function, such as
Alzheimer, Parkinson, Huntington, and Down syndrome. Accord-
ingly, the endolysosomal system has been called a ‘‘genetic hot-
spot” for neurodegenerative diseases [46]. Accumulation and
abnormal processing of the Amyloid precursor protein, a feature
characteristic for Alzheimer disease, occurs also in NPC-disease,
type 1, which indicates that disturbance of endosomal membrane
turnover leads to an Alzheimer-like pathology [47].5. Lysosomal degradation of membranes
Membranes are essentially composed of amphiphilic lipids and
proteins. Complex lipids such as glycerolipids and sphingolipids as
well as proteins have to be degraded within the process of endo-
somal/lysosomal membrane digestion, so that the ﬁnal degrada-
tion products can leave the compartment. While soluble
macromolecules such as proteins, glycoproteins, or oligosaccha-
rides can be degraded directly by soluble enzymes, the degradation
of membranes requires a much more complex disintegration and
degradation system [48]. Lysosomal digestion of membranes is
essential for cellular membrane homeostasis. Breakdown-products
of glycosphingolipids are continuously recycled and re-utilised in
salvage processes [49].
In late endosomes, membrane proteins and lipids targeted for
degradation undergo a sorting process to intraendosomal mem-
branes, which are degraded in the lysosomes, while the integrity
of the lysosomal limiting membrane has to be preserved. However,
pathophysiological factors can lead to the permeabilization of the
lysosomal perimeter membrane: Higher concentrations of the
membrane-active substances fatty acids and sphingosine can lead
to damage of the perimeter membrane and subsequent necrosis or
apoptosis [50]. Therefore, the release of these hydrophobic prod-
ucts of bulk lipid degradation has to proceed in a controlled fash-
ion. This is achieved by a buffering mechanism according to
which these hydrophobic substances are liberated within a twodi-
mensional lipid environment in a controlled fashion. Soluble en-
zymes lead to their release in a reversible way in the sense that
they catalyze also the corresponding back-reaction: Acid cerami-
dase cleaves the degradation product of most sphingolipids and
glycosphingolipids, ceramide, into sphingosine and fatty acid in a
reversible way. If the concentrations of these cleavage products
are high, the reverse reaction can be catalyzed, since both compo-
nents are present in the bilayer and diffusion into the lysosol is not
fast enough [51]. Especially the accumulation of the cationic
amphiphile sphingosine would impair other lysosomal degrada-
tion steps, presumably in a similar manner as by the cationic
amphiphile desipramine (see above). A similar effect is exerted
by acid phospholipase A2, the enzyme required for the lysosomal
degradation of glycerolipids: this enzyme also catalyzes the
reverse reaction, the formation of glycerophospholipid from its
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alcohols present in intralysosomal membranes, for example ceramide
[52], but also exogenously added alcohols [53].
Destabilization of the lysosomal membrane can be associated
with oncogenic transformation. Its permeabilization in response
to TNFalpha can occur in a caspase-dependent and also -indepen-
dent way with the consequence of apoptotic cell death [54].
A view on the molecular mechanisms of membrane digestion
reveals a complex machinery composed of lipids of inner lyso-
somal membranes and lysosomal proteins. This system ensures
selective degradation of inner membranes (review: [48,55]).6. Entry pathways
Components of cellular membranes reach the lysosomes from
the plasma membrane via endocytosis or from the trans Golgi net-
work. Also lysosomal proteins are sorted via these routes [56]. For-
eign membranes and membrane components enter the cell via
endocytosis, e.g., after phagocytosis or via receptor-mediated
endocytosis of lipoproteins. During endocytosis, eukaryotic cells
internalize areas of the plasma membrane, in part together with
foreign material, via different mechanisms and deliver them to
early endosomes [57–60]. As an alternative to endocytosis, mem-
branes, macromolecules, but also whole organelles can enter lyso-
somes by the different pathways of autophagy [61–63]. After
fusion of the autophagosome with endosomes or lysosomes, mac-
roautophagy requires degradation of the single membrane of the
autophagic body, which separates the engulfed cytoplasmic space
from the lysosol. At least in the yeast vacuole, this has to occur
in a pH-dependent manner [64], before the autophagosomal con-
tent can be degraded by the lysosomal hydrolases. Autophagy is
of special relevance for membrane degradation since it appears
to be a source of BMP (erroneously also called lysobisphosphatidic
acid). This negatively charged lipid is highly enriched in the inner
membranes of lysosomes and is required for degradation of their
lipid components (see below). It is derived from phosphatidylglyc-
erol generated in the ER and from cardiolipin of mitochondria [65–
69], which reaches the lysosome as a component of mitochondria
by macroautophagy.7. Lysosomal sphingolipid degradation
Major insight into the process of membrane digestion came
from the investigation of glycosphingolipid catabolism. Glyco-
sphingolipids (Fig. 1) are ubiquitously expressed on eukaryotic cell
surfaces. They are composed of a hydrophobic ceramide moiety
and an extracytoplasmic oligosaccharide chain [70]. Combination
of different carbohydrate residues, anomeric linkages, and addi-
tional modiﬁcations of the carbohydrate and lipid moiety lead to
a variety of naturally occurring glycosphingolipids that are biosyn-
thetically formed in a combinatorial manner [71]. A great variety of
glycosphingolipid structures is known, which depend on species
and cell type. Neuronal cells are especially rich in acid glyco-
sphingolipids of the ganglio-series. This is the reason why defects
in ganglioside degradation affect especially the nervous system.
After endocytosis, glycosphingolipids are degraded on the sur-
face of intralysosomal membranes in a sequential pathway. Soluble
glycosidases cleave off monosaccharide units from the non-reduc-
ing end of the glycosphingolipid oligosaccharide chain in a step-
wise manner. For the degradation of substrates with short
oligosaccharide chains of less than four sugars, these enzymes
need the assistance of small glycoprotein cofactors, the sphingo-
lipid activator proteins, the saposins A–D and the GM2 activator
protein [72]. Results from in vitro-experiments indicate that in
addition to enzymes and activator proteins, an appropriate mem-brane lipid composition is required for degradation. Most hydro-
lases are water-soluble polycations at a lysosomal pH of less
than 5.0. They bind to negatively charged intraendosomal and
intralysosomal membranes, but in the absence of activator pro-
teins, they are not able to degrade their membrane-bound sub-
strates. An exception is acid sphingomyelinase, which hydrolyses
membrane-bound sphingomyelin slowly even in the absence of
an activator protein, which is obviously due to its N-terminal sapo-
sin-homology domain [73].
For glycerophospholipids [74] and for non-glycosylated sphin-
golipids like ceramide and sphingomyelin [75], also non-lysosomal
degradation steps are known, which apparently do not need the
assistance of an additional activator protein. A cytoplasmic gluco-
sylceramide-cleaving enzyme, which is not deﬁcient in Gaucher’s
disease, contributes to the degradation of the cytoplasmic gluco-
sylceramide pool [76,77].
During lysosomal membrane degradation, the integrity of the
limiting membrane has to be preserved. Historically, this led to
the assumption of two distinct pools of membranes, which have
to be present in the late endosomal/lysosomal compartment [78].
Ultrastructural examination of cells from patients with defects of
glycosphingolipid degradation showed that non-degradable lipids
accumulate as multi-vesicular storage bodies in diseases like the
GM1-gangliosidosis [79] or the combined sphingolipid activator
protein deﬁciency [80]. This gave the ﬁrst hint for the assumption
of a topological differentiation of the two membrane pools [78].
The model that membrane components – lipids and proteins –
reach the lysosomal compartment either as intraendosomal
membranes, or as part of the limiting membrane (Fig. 2) has been
supported by a series of observations [81]. Both membranes differ
in their lipid- and protein composition. The lysosomal leaﬂet of the
limiting membrane is covered with a thick glycocalix that protects
the membrane from the attack by the membrane-degrading
enzymes present in the lysosol. This glycocalix is formed by
lysosomal integral membrane proteins, which are highly N-glycos-
ylated with polylactosamine units and therefore highly resistant
towards lysosomal digestion [82]. Apparently the degrading
enzymes present within the lumen of the lysosome, cannot access
their substrates through this glycocalix. Already more than 30
years ago it was demonstrated that after its incorporation into
the limiting lysosomal membrane, plasma membrane-derived gan-
glioside GM3 is protected from degradation [83], while it is easily
degraded during the constitutive process of membrane turnover
[84].
Years after the model of inner membranes as degradation plat-
forms for membranes has been proposed, proteins coordinating the
generation of inner vesicles in endosomes have been identiﬁed
(reviews: [85,86]) The formation of multivesicular bodies (MVBs)
starts with inward budding of the limiting endosomal membrane
and requires the sequential action of three endosomal sorting com-
plexes required for transport, ESCRT-I,-II,-III [87]. One sorting sig-
nal sufﬁcient for protein targeting to inner membranes is the
ubiquitinylation of proteins [88]. This signal appears to be con-
served between yeast and higher eukaryotes, but also ubiquitin-
independent factors have been reported (review: [89]).8. Functional aspects of membrane lipid sorting in the
endocytic pathway
8.1. Anionic lipids as activators of sphingolipid degradation
The lipid composition of cellular membranes is precisely regu-
lated and highly speciﬁc for different cell types, organelles, and
the two leaﬂets of the lipid bilayer [90]. During endocytosis and
maturation of endosomes, the luminal pH decreases, and the com-
Fig. 2. Model of endocytosis and lysosomal digestion of membranes. Glycosphingolipids (GSL) are highlighted on the plasma membrane (PM) and on internal membranes,
and gradients of pH, cholesterol (Chol), BMP, sphingomyelin (SM), and ceramide (Cer; hypothetical) are shown (modiﬁed from: [55,48]).
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somes resemble the plasma membrane in their composition, mem-
brane-stabilizing cholesterol, other sterols, and phosphatidylserine
are sorted out, and BMP levels increase drastically. In BHK cells,
two populations of intralysosomal membranes were found, and
in one of them, BMP accounted for up to 70% of total phospholipids
[91]. BMP is not present in the limiting lysosomal membrane [115],
but is required for sphingolipid degradation on inner membranes
of the acidic compartments.
In addition to that of bulk lipids, also levels of phosphoinosi-
tides change from phosphatidylinositol-4,5-bisphosphate
(PtdIns(4,5)P2) on the plasma membrane to PtdIns3P on early
endosomes, and PtdIns(3,5)P2 on late endosomes [92]. Sphingo-
lipid-containing membranes of autophagocytic bodies should con-
tain lower amounts of cholesterol, but metabolic precursors of
BMP, and might be degraded in a similar manner.
BMP (Fig. 1) is a characteristic anionic phospholipid on the sur-
face of intralysosomal membranes. Its unusual sn1,sn10-conﬁgura-
tion leads to its higher resistance to the action of phospholipases
than normal phospholipids [93]. Together with smaller amounts
of other anionic lipids like phosphatidylinositol [94] and dolichol
phosphate [95], it accounts for the negative charge of intralysosomal
membranes and is also required for the formation of intraendoso-
mal membranes. The fatty acid composition of BMP is tissue-
dependent, with oleic acid as the major acyl residue of BMP from
BHK cells, while highly unsaturated BMP is found in testis and
rat uterine stromal cells (W.W. Christie, www.lipidlibrary.co.uk/
Lipids/lysobpa/index.htm). A protein that binds to BMP-containing
membranes [96], Alix/AlP1, plays a role in sorting to inner mem-
branes [97,98] intramolecular vesicle ﬁssion, and fusion during
lysosome maturation [99,100]. Alix knockdown leads to a decrease
in levels of BMP and cellular cholesterol; also the amount of intra-
endolysosomal membranes is reduced [101].
In vitro results indicate that packing and conformation of BMP
favors budding, stabilization [102], and fusion [91] of vesicles at
acidic pH. Moreover, different endosomal and lysosomal lipid
transfer proteins require an optimal lipid composition of the mem-
brane they have to interact with, as in the case of the NPC2-protein
that extracts sterols from membranes (see below). Saposin A [103]
and saposin B [104] extract membrane lipids best from choles-terol-poor and BMP-rich liposomes, while neutral lipid bilayers
are resistant towards solubilization even at acidic pH values. High
amounts of BMP and low amounts of membrane-stabilizing cho-
lesterol in internal lysosomal membranes appear to be required
for the degradation of glycosphingolipids. The presence of BMP in
these vesicles increases the ability of the GM2-activator to solubi-
lize lipids [105]. In addition, negatively charged lysosomal lipids
also stimulate the interfacial hydrolysis of membrane-bound gan-
glioside GM1 by GM1-b-galactosidase [106], of ganglioside GM2 by
b-hexosaminidase A [105], of the sulfated gangliotriaosylceramide
SM2 by b-hexosaminidases A and S [107] in the presence of the
GM2-activator protein, of sphingomyelin by acid sphingomyeli-
nase [73], and of ceramide by acid ceramidase [108]. Glucosylcer-
amide degradation by glucosylceramide-b-glucosidase is enhanced
in the presence of saposin C in membranes containing negatively
charged lipids such as phosphatidylserine, phosphatidylglycerol,
and phosphatidic acid [109–111].
Enzymes like acid sphingomyelinase [18] and acid ceramidase
[112] are released from intralysosomal membranes after treatment
with the cationic amphiphile desipramine, and are rapidly de-
graded. Also the activity of acid phospholipase A2 towards mem-
branes is increased when they contain negatively charged lipids
and is reduced in the presence of a cationic amphiphilic drug, ami-
odarone [113].
8.2. Cholesterol, sphingomyelin, and ceramide
Since saposins and the GM2-activator required for membrane
degradation extract lipids best from cholesterol-poor and BMP-rich
membranes, intraendosomal membranes have to adjust their lipid
composition, so that they can be degraded after their delivery to
lysosomes. In endosomes, cholesterol is removed from inner mem-
branes by the proteins NPC1 and NPC2 [114] (Fig. 3). Cholesterol,
the major lipid molecular species of the plasma membrane and
in membranes of early endosomes is nearly completely absent in
inner lysosomal membranes [115]. It enters the endosomal com-
partment via membrane recycling, non-vesicular pathways, or
lipoprotein uptake, and can leave the endosomes to the Golgi appa-
ratus, the ER, or can return to the plasma membrane [116]. While
exogenous cholesterol can trafﬁc to intracellular sites within a few
SM               GlcCer
Ceramide
Sphingosine + Fatty acid
pH 5.5
pH 4.8
Glycocalix
NPC-2
NPC-1
Ring Finger
Late
endosome
intraendosomal
vesicle
ASM
?
Fig. 3. Model for lipid sorting on the stage of late endosomes: at pH 5, acid sphingomyelinase degrades sphingomyelin and produces ceramide on the surface of endosomal
vesicles. Decrease of sphingomyelin and increase of ceramide enhances the availability of cholesterol on inner membranes and facilitates its binding to NPC2 (Abdul-
Hammed, Breiden, Adebayo, Babalola, Schwarzmann, and Sandhoff, unpublished), which transfers cholesterol to the N-terminal domain of NPC1 according to Kwon et al.
[206]. NPC1 enables cholesterol transfer through the glycocalix. Bulk production of glucosylceramide by degradation of most glycosphingolipid series occurs at lower pH,
presumably on later stages of lysosomal maturation. Ceramide formation is reversible to ensure controlled formation of potentially harmful sphingosine and fatty acids (see
text).
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puriﬁed lysosomal membranes is more than 100-fold slower than
that from intact cells [117]. This exit from lysosomes can be dras-
tically stimulated by a cytoplasmic binding protein, sterol carrier
protein-2 (SCP-2) [118].
Experiments using exogenous addition of ganglioside GM1
derivatives bearing a photoafﬁnity label to cultured ﬁbroblasts
and other cell types showed a high degree of crosslinking to
cholesterol, which decreases during endocytosis from 89% to
less than 5% of all lipid derivatives, crosslinking with BMP was
elevated from 0% to 45%, whereas crosslinked phosphatidylcholine
and sphingomyelin remained nearly unchanged (von Coburg and
Sandhoff, unpublished). These results are in agreement with those
obtained by electron microscopy [115,119,120]. For the molecular
aspects of cholesterol exit from endosomes, see the chapter on
NPC2 below.
During the maturation of intraendosomal/intralysosomal mem-
branes, the levels of ceramide should increase at the expense of
sphingomyelin, which is rapidly degraded to ceramide by acid
sphingomyelinase. According to a simpliﬁed view, sphingomyelin,
a cholesterol-binding lipid, is replaced by ceramide, a cholesterol-
competitor [121], during the processing of inner membranes in the
late endosomes. Actually, the effect of the concentration of these
lipids on membrane properties and domain formation is much
more complicated: At low cholesterol concentrations, ceramide
segregates into gel domains, which disappear, when cholesterol
levels increase. This is independent of the presence of sphingomy-
elin. Also, ceramide is more soluble in cholesterol-rich ﬂuid mem-
branes than in cholesterol-poor ones, and the solubility of
cholesterol in ceramide domains is low [122]. Ceramide, the com-
mon product of glycosphingolipid- and sphingomyelin catabolism
can stabilize lipid phases, i.e., microdomains, more efﬁciently than
cholesterol [121,123,124].
In endosomes, ceramide is produced largely by sphingomyeli-
nase-catalyzed cleavage of sphingomyelin (Fig. 3). Glucosylcera-
mide is formed during the degradation of most glycosphingolipid
series found in mammals [70], but in the lysosomes. Therefore, glu-
cosylceramide cleavage cannot be expected to contribute signiﬁ-
cantly to the ceramide pool on intraendosomal membranes.
There, ceramide, a ‘‘membrane-intercalating agent” that can re-
place cholesterol via enhancing its thermodynamic activity (escape
potential) in the bilayer, should facilitate cholesterol loading on
NPC2, analogous to an increased cholesterol transfer on cyclodex-trin, as determined in vitro [125]. On the other hand, sphingomy-
elin inhibits cholesterol transfer by NPC2 (Abdul-Hammed,
Breiden, Adebayo, Babalola, Schwarzmann, and Sandhoff, unpub-
lished). This points to a major role of acid sphingomyelinase for
cholesterol exit. Cholesterol is transferred through the glycocalix
of the perimeter membrane after its transfer to NPC1 (see below)
and is further transported and processed.
During endosomalmaturation, the luminal pHdecreases. The en-
zymes that lead to generation of ceramide have higher pH-optima
than acid ceramidase, which converts ceramide into sphingosine
that is positively charged at the pH of the lysosol. Glucosylcera-
mide-b-glucosidase that converts glucosylceramide into ceramide
and acid sphingomyelinase that converts sphingomyelin into cera-
mide have pH-optima of about 5.5 [126,73,75], while the pH-opti-
mum of acid ceramidase is in the range of 3.8–4.2 in the presence
of saposin D [108,127]. This should lead to a continuous increase
of ceramide levels within the intralysosomal membranes during
the process of endosomal maturation. The replacement of sphingo-
myelin by ceramide should facilitate cholesterol exit out of this
membrane population by the cholesterol-carrier NPC2.
8.3. Lysosomal lipid-binding proteins are required for membrane
degradation
In vivo, the lysosomal degradation of inner membranes is
dependent on the presence of certain proteins and lipids. In addi-
tion to water-soluble hydrolases, lysosomal lipid-binding proteins
(LLBPs) and acidic lipids, especially BMP, are required for mem-
brane degradation. Lipid-binding- and transfer proteins of differ-
ent, also non-endo/lysosomal subcellular localization are crucial
for the metabolism of different lipid classes, such as fatty acids,
sphingolipids [128,129], and intracellular trafﬁcking and metabo-
lism of cholesterol. They include other proteins of saposin-like
structure [130], CERT, a protein that transfers ceramide from
the ER to Golgi membranes [131], fatty acid-binding proteins
(review: [132]), or the glycolipid binding protein, a cytosolic
transfer protein for glycolipids of unknown function [133].
Although lipid-metabolizing enzymes and lipid-antigen-present-
ing CD1-proteins can be regarded as lipid-binding proteins
[134,135], LLBPs in the narrow sense encompass the saposins
A–D and the GM2 activator protein. An endosomal lipid-binding
protein is NPC2. LLBPs play a role in membrane fusion, disintegra-
tion, and metabolism, and also in the transfer of lipids to proteins
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killer cells (review: [136]).
It has been known for more than 30 years that glycosphingo-
lipid degradation requires the presence of certain of LLBPs, the
sphingolipid activator proteins [72]. While other membrane com-
ponents like phospholipids can apparently be degraded without
additional cofactors that make their lipid ligands accessible for
the degrading enzymes, sequential hydrolytic cleavage of glyco-
sphingolipids with short carbohydrate chains of four or less sugars
is critically dependent on the presence of lysosomal lipid-binding
proteins, and of negatively charged lysosomal lipids (see above).
In the absence of detergents that are able to solubilize lipids, mem-
brane-bound glycosphingolipids with short carbohydrate chains
are not sufﬁciently accessible to the water-soluble enzymes pres-
ent in the lysosol in the absence of activator proteins [137,106].
In vitro, synthetic water-soluble glycosphingolipids (GSLs) with
either short chain fatty acids or with no fatty acids (lysoGSLs)
can already be hydrolyzed by the water-soluble enzymes in the ab-
sence of SAPs. Sphingolipid activator proteins known to date are
encoded by two genes: one gene encodes the GM2-activator pro-
tein, the other encodes prosaposin, also called SAP-precursor pro-
tein (review: [72]). This protein is posttranslationally processed
to four homologous mature proteins, the saposins A–D or saps
A–D. These activator proteins act on the intraendosomal/intralys-
osomal membrane pool and lead to the selective degradation of
membrane lipids without impairment of the perimeter membrane
and therefore of lysosomal integrity.
8.4. Saposins
Saposins are water-soluble lysosomal lipid-binding and -trans-
fer glycoproteins of about 8–11 kDa molecular weight (for review
see: [72]). They belong to a family of saposin-like proteins with
conserved three-dimensional folds [130] and occur as homo- and
heterodimers and -oligomers. The solution structures of NK-lysine
[138], of the pore-forming peptide of Entamoeba histolytica [139],
of saposinC [140], and the x-ray structures of unglycosylated hu-
man recombinant saposin A and saposin C [141], saposin B [142],
saposin C, and saposin D [143] are known and show high structural
similarity.
Saposins share lipid-binding- and membrane perturbing prop-
erties. For example, the protozoan parasite Entamoeba histolytica
expresses pore-forming proteins of saposin-like structure, the
amoebapores. Like eukaryotic NK-lysin and granulysin, these pro-
teins are able to permeabilize the membranes of target cells, which
accounts for their antimicrobial activity [144]. Although the four
mammalian saposins share a high degree of homology and similar
properties, they act differently and show different speciﬁcities.
8.5. Prosaposin
Prosaposin, a 70 kDa glycoprotein, is proteolytically processed
to the mature activator proteins in the late endosomes and lyso-
somes [145–147]. Initially, the non-signal aminoterminal peptide
preceding the saposin A-domain is cleaved off, then saposin A is re-
leased with initial formation of a sap B–D trimer that is subse-
quently cleaved via sapB/C and sapC/D dimers to the mature
saposins [148]. Prosaposin is intracellularly targeted to the lyso-
somes via mannose-6-phosphate receptors, by sortilin [149], or se-
creted and re-endocytosed after binding to mannose-6-phosphate
receptors, LRP, or mannose receptors [150].
Rare mutations in the start codon of the prosaposin gene lead to
a complete deﬁciency of the protein and of all four mature sapo-
sins. Since prosaposin is rapidly cleaved in the acidic compart-
ments, it can be assumed that the protein itself plays no role for
membrane digestion. Prosaposin deﬁciency in human patientsand mice [151] causes simultaneous storage of many sphingolipids
and glycosphingolipids accompanied by a dramatic accumulation
of intralysosomal membranes. In cultured cells, this storage can
be completely reversed by treatment with human prosaposin, as
demonstrated in prosaposin deﬁcient ﬁbroblasts [152].
8.6. Saposin A
Saposin A is required for the degradation of galactosylceramide
by galactosylceramide-b-galactosidase. Genetically engineered
mice that carry a mutation in the saposin A-domain of the Sap-pre-
cursor accumulate galactosylceramide and suffer from a late-onset
variant form of Krabbe disease [153].
8.7. Saposin B
Saposin B was the ﬁrst activator protein that had been identi-
ﬁed as so-called sulfatide-activator in 1964 [154]. It mediates the
degradation of sulfatide by arylsulfatase A, of globotriaosylcera-
mide and digalactosylceramide by a-galactosidase A, of other gly-
colipids [155], for example together with the GM2-activator
protein for the degradation of ganglioside GM1 [106].
The X-ray structure shows a shell-like homodimer that encloses
a large hydrophobic cavity [142]; the monomers are composed of
four amphipathic a-helices arranged in a long hairpin that is bent
into a simple V-shape. Like in the case of the GM2-activator, two
different conformations of the saposin B-dimers were visible, and
a mode of action similar to that of the GM2-activator has been pro-
posed: The open conformation is supposed to interact directly with
the membrane, to promote a reorganization of the lipid alkyl
chains, and to extract the lipid ligand, which is accompanied by a
change to the closed conformation. The substrate is then exposed
to the enzyme in a water-soluble activator–lipid complex [156],
consistent with the previous observation that saposin B can act
as a lipid-transport protein [157].
The inherited defect of saposin B leads to an atypical form of
metachromatic leukodystrophy [158] with accumulation of sulfa-
tides, digalactosylceramide, and globotriaosylceramide (review:
[72]). Saposin B-knockout mice display enhanced levels of hydroxy
and non-hydroxy fatty acid-containing sulfatides especially in
brain and kidney [159]. The interaction of saposins A and -B with
immobilized lipids was characterized by surface plasmon reso-
nance [103,104]. Glycosylated saposins bind to lipid bilayers at
acidic pH and are able to extract lipids. The disintegration of lipo-
somes is increased by high BMP levels, whereas cholesterol stabi-
lized the membranes. The carbohydrate part of saposins turned
out to be crucial for their function, since unglycosylated proteins
showed increased binding, but reduced extraction capacity. Vari-
ant proteins without glycosylation site from patient lost their li-
pid-extraction capacity almost completely. X-ray and NMR
structure determination showed variations in the structure motif
common for saposins on different conditions such as changes of
pH value, addition of detergents, and of lipid ligands [160–162].
Data from atomic force microscopy favor a multistep mechanism
in lipid mobilization by saposins: after formation of a transient
layer on the surface of intraluminal membranes, a conformational
change occurs that allows interaction of hydrophobic amino acid
residues with the acyl chains embedded in the bilayer [163]. Other
potential functions of saposin B are only beginning to emerge, e.g.,
as a binding protein for coenzyme Q10 in urine and cultured cells
[164] and in vitro also for gamma-tocopherol [165].
8.8. Saposin C
Saposin C has been initially isolated from spleen of patients of
Gaucher disease. It occurs as a homodimer and is required for
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mide-b-glucosidase [166]. Saposin C also renders protease-resis-
tance to glucosylceramide-b-glucosidase inside the cell [167].
The solution structure of saposin C [140] consists of ﬁve tightly
packed a-helices that form the half of a sphere. All charged amino
acids are solvent-exposed, while the hydrophobic residues are con-
tained within the protein core. In contrast to the mode of action of
the GM2-activator and of saposin B, saposin C can directly activate
glucosylceramide-b-glucosidase as an allosteric effector
[109,166,168]). Saposin C binds to membranes in a pH-controlled,
reversible manner [169], supports the interaction of the enzyme
with its membrane-bound substrate in the presence of anionic
phospholipids, and is able to destabilize such vesicles [137]. Sapo-
sin C deﬁciency leads to an abnormal juvenile form of Gaucher dis-
ease with an accumulation of glucosylceramide [170,171]. Atomic
force microscopy suggests the view that saposin C locally alters
membrane regions preferentially at edges of membrane defects
for subsequent attack by the saposin C-b-glucosidase complex
[172].
8.9. Saposin D
Saposin D stimulates lysosomal ceramide degradation by acid
ceramidase in cultured cells [173] and in vitro [108]. It is able to
bind to vesicles containing negatively charged lipids and to solubi-
lize them at an appropriate pH [174]. Saposin D-deﬁcient mice
accumulate ceramides with hydroxylated fatty acids mainly in
the brain and in the kidney [175]. Mice with a combined deﬁciency
of saposin C and saposin D store glucosylceramide and alpha-hy-
droxy fatty acid-containing ceramides; in addition, also prosaposin
trafﬁcking is impaired, and levels of saposins A and B are reduced
[176].
8.10. The GM2-activator
The GM2-activator is a glycoprotein with a molecular weight of
17.6 kDa in its deglycosylated form [72] and is required for the
in vivo degradation of ganglioside GM2 by b-hexosaminidase A
[177]. b-Hexosaminidase A can cleave glycolipid substrates on
membrane surfaces only if they extend far enough into the aque-
ous phase. In the absence of detergents, the degradation of gangli-
oside GM2 occurs only in the presence of the GM2 activator
protein.
Inherited deﬁciency of the GM2-activator protein leads to the
AB variant of GM2-gangliosidoses, in which lipid accumulation in
neuronal cells leads to the early death of the patients [178]. The
X-ray structure of the non-glycosylated protein shows a hydropho-
bic cavity for the ceramide moiety of ganglioside GM2 [179,180]. A
model for its mode of action that considers also data from photo-
afﬁnity labeling is shown in Fig. 4 [181]. It forms stoichiometric,
water-soluble glycolipid–protein complexes that are the physio-
logical Michaelis–Menten-substrates of b-hexosaminidase A
[177]. As concluded from sedimentation experiments, the GM2-
activator is able to extract ganglioside GM2, but also other lipids,
in a pH-dependent fashion from membranes. BMP increases the
extraction efﬁciency, and less than 15% of the activator protein re-
mains membrane-associated. Remarkably, the binding characteris-
tics of the GM2-activator are altered by the presence of a His-tag
[182].
In vitro, the GM2-activator acts as a lipid transfer protein that
can carry lipids from donor to acceptor liposomes [178]. In Lang-
muir experiments, the GM2-activator protein is able to penetrate
into a phospholipid monolayer, but only when the lateral pressure
is below a critical value of 15–25 mN/m, dependent on the lipid
composition [183]. The transfer capacity of GM2AP was quantiﬁed
in a liposomal ﬂuorescence or Förster resonance energy transfer(FRET) assay [184] based on novel NBD-labeled glycolipid sub-
strates [185].
In addition to its function as a ganglioside transfer protein, the
GM2-activator binds also other lipids like phosphatidylcholine and
platelet activating factor (PAF) and inhibits its action [186]. The
observation that also lysoPAF was detected in the X-ray structure
of the protein–lipid complex raises the possibility that the GM2-
activator might also display hydrolase activity towards this lipid
[187]. This has also been observed for phosphatidylcholine, which
can be cleaved by the activator in a phospholipase A2-like manner
with a pH-optimum of 6 [188]. GM2-activator orthologs might
serve different functions in other organisms. In Drosophila, a
homologous proteins acts as a pheromone binding protein [189],
and in a nematode, Trichinella spiralis, a secreted protein appar-
ently without the domain required for binding to hexosaminidase
does not stimulate GM2-degradation by b-hexosaminidase A, but
inhibits PAF-induced chemotaxis [190].
8.11. NPC2
Niemann–Pick disease protein C2 (NPC2) is a late endosomal
lipid-binding protein [191], and together with proteins like Insig,
SCAP, LXR, HMG-CoA-reductase, or NPC1, it belongs to the group
of cholesterol-binding proteins, whose members have different
subcellular localization [192]. An inherited disorder, in which
intracellular trafﬁc of cholesterol is impaired, is Niemann–Pick dis-
ease, type C (NPC) [193,194]. NPC is a neurodegenerative disorder
characterized by accumulation of cholesterol in endolysosomes,
and secondarily also of neutral and acidic glycolipids, especially
gangliosides GM3 and GM2 [195], sphingomyelin (less than in Nie-
mann–Pick disease, types A and B), BMP, and phospholipids [194].
NPC is due to mutations in the genes encoding the NPC1- [196]
or the NPC2-protein [197]. NPC1-deﬁciency accounts for 95% of
NPC-cases [198]; the other cases are due to mutations in the gene
encoding the NPC2-protein [199]. This protein has been identiﬁed
before as a lysosomal glycoprotein that can bind cholesterol with
high afﬁnity in a 1:1 stoichiometry [200] as well as other sterols
[201]. In vitro, it acts as a transport protein for cholesterol to and
from liposomes [202,203]. Lysosomal conditions (high BMP content
of the membranes, low pH value) stimulate the transport between
donor and acceptor liposomes [204]. NPC2 most likely mediates
cholesterol transport between intraendosomal membranes and
from the internal membranes to the NPC1-protein, an integral pro-
tein of the perimeter membrane. Crystal structures of NPC2 with
cholesterol sulfate [205] and of the N-terminal domain of NPC1 in
complex with 25-hydroxy-cholesterol suggest the following model
[206]: NPC2 binds cholesterol so that its isooctyl side chain is bur-
ied in a hydrophobic cleft and its hydroxyl group is exposed to the
aqueous surroundings. The N-terminal domain of NPC1, however,
binds cholesterol in the opposite orientation: the hydroxyl-group
is buried in the domain, and the hydrophobic isooctyl side chain
is exposed. Therefore, cholesterol can be transferred from NPC2 to
NPC1 without re-orientation. This is subsequently inserted into
the lysosomal perimeter membrane, from where it enters sites in
the cytoplasm by an unknown mechanism. The observation that
NPC1 might be required for copper transport out of endosomes
might also account for the pathogenesis of NPC1-disease [207].
The fact that insolubility of storage material in lipidoses deter-
mines the phenotype is illustrated by the fact that oral treatment
of the NPC1 disease model mice with 2-hydroxypropyl-beta-cyclo-
dextrin, which is able to extract and solubilize cholesterol and
other lipids, is able to reverse the lysosomal transport defect
[208]. Since NPC2 acts only as a sterol transfer protein, it is not
clear how NPC2 might be involved in loading of a glycolipid on
CD1d, as reported for the only known of the selecting ligands of
NKT cells in the thymus, isoglobotrihexosylceramide [209,210].
Fig. 4. Model for GM2-activator stimulated hydrolysis of ganglioside GM2 by human b-hexosaminidase A [181]. The GM2-activator contains a hydrophobic cavity for binding
of the ceramide portion of GM2 or other lipids. One of the surface loops contains the substrate-binding site (V153–L163) and controls the entrance to the cavity. In the open
conformation, the empty activator binds to the membrane with the aid of hydrophobic loops and penetrates into the hydrophobic region of the bilayer. The lipid recognition
site of the activator can interact with the substrate, and its ceramide moiety moves inside the hydrophobic cavity. The lipid loaded activator can change to the closed
conformation, becomes more water soluble and might leave the membrane. In solution or at the membrane surface, it present gangliosides GM2 or GM1 to water-soluble
hydrolases.
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The lysosome serves not only diverse housekeeping functions,
but also plays a role in immune responses, e.g., for the presentation
of exogenous and endogenous antigens [211]. Intracellular mate-
rial present in the cytoplasm is delivered to lysosomes by autoph-
agy, their degradation products loaded on MHC class II proteins,
and presented by them to T-lymphocytes [212]. In addition to their
role in membrane degradation, lysosomal lipid-binding proteins
are required for the presentation of lipid and glycolipid antigens.
In humans, they are needed for loading of the four MHC-I-like gly-
coproteins CD1a–d that present lipid antigens to T-cells. A ﬁfth
protein, CD1e, is synthesized as an integral membrane protein,
from which a soluble lipid binding domain is released by proteol-
ysis within the lysosomes of mature dendritic cells [213]. In addi-
tion to the saposins and the GM2-activator (review: [136]), a major
role in the transfer of lipid antigens to membrane-resident CD1-
proteins has to be attributed to this protein [214,215].
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